AlphAIalphai — Financial news for AI agents
Stock TitanMAY 162 min read$ENLV

Enlivex (NASDAQ: ENLV) gets Nasdaq notice over sub-$1 bid price and listing risk

Enlivex Ltd. (NASDAQ: ENLV) has received a notice from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has an initial 180-day period, until November 9, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to comply could lead to delisting, though Enlivex may be eligible for an additional 180-day period if other listing standards are met.

Original reporting
Stock Titan
Published May 16, 2026, 3:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 16, 2026, 4:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$ENLV
Neutral
medium confidence
Mentioned
$ENLV
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$ENLVNeutralMed
01

Why it matters

The regulatory notice could lead to increased stock volatility and potential delisting if the company does not act within the specified period.

02

Market read

The news is relevant for traders holding or considering trading ENLV, especially those with short-term trading horizons.

03

What to watch

Potential for strategic corporate actions or investor support that could mitigate delisting risk and stabilize the stock.

Timing: Immediate to short-term (next 180 days)

Background

Enlivex Ltd. is a biotech company listed on NASDAQ that has failed to meet the minimum bid price requirement, triggering a Nasdaq notice.

Company-level read

Ticker impact

$ENLVNeutralMedium confidence
Context

The news pertains directly to Enlivex Ltd.'s listing status and potential delisting risk.

Expected impact

Potential short-term decline if the company fails to regain compliance; possible stabilization or recovery if compliance is achieved.

Evidence & confidence

The news indicates a regulatory compliance issue that could impact investor confidence. However, the company's ability to regain compliance within the specified period introduces uncertainty, making the impact moderate.

Market effects

Sector

Potential increased volatility in biotech and life sciences sectors with similar listing standards.

Regional

Limited; primarily affects NASDAQ-listed biotech companies.

Global

Low; specific to NASDAQ and U.S. markets.

Counterpoint

What could challenge this read

The company might implement measures to quickly regain compliance, leading to a short-term dip followed by a rebound.

Key entities

  • Regulatory Body
    Nasdaq

    The stock exchange that enforces listing standards.

  • Company
    Enlivex Ltd.

    Biotech firm facing listing compliance issues.

Read at source← All news

Related articles

JUL 29
$ENLVMed

FDA Grants Allocetra RMAT Designation for Knee Osteoarthritis

Enlivex Ltd. (Nasdaq: ENLV) said its management will host a July 30, 2026 investor webinar covering a recently announced private placement, its Rain protocol-based RAIN treasury strategy, and clinical progress for Allocetra. Enlivex also reported the FDA granted Allocetra RMAT designation for symptomatic knee osteoarthritis in patients aged 64+.

stocktitan.net3 min
JUL 13
$ENLVMedAI 8/10

Enlivex's Allocetra Secures FDA RMAT Designation For Knee Osteoarthritis Treatment

Enlivex Ltd. (ENLV) said the FDA granted RMAT designation to its Allocetra therapy for age-related symptomatic knee osteoarthritis in older adults. The RMAT decision cites results from its completed Phase I/IIa trial showing statistically significant improvements in pain and function vs placebo, durable to six months. Enlivex is starting a Phase IIb trial enrolling 182 patients and plans an FDA Type B meeting.

rttnews.com3 min
JUL 13
$ENLVMedAI 8/10

Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA By Investing.com

Investing.com reports the FDA granted RMAT designation to Enlivex’s experimental immunotherapy Allocetra for age-related knee osteoarthritis in patients 64+. The status may enable more frequent early FDA interactions and could support accelerated approval. Enlivex is running a Phase IIb trial to enroll 182 patients, with first U.S. dosing done and topline data expected by end of Q2 2027.

investing.com3 min
MAY 25
$PDDMedAI 8/10

Housing, Employment Numbers Featured in Short Week in U.S.

The article previews a short U.S. and Canada market week after Memorial Day, highlighting housing, confidence, jobs, and earnings. It lists U.S. EPS results for PDD, AutoZone, Elbit, Salesforce, Synopsys, Marvell, Costco, Dell, and Autodesk, plus Canada banks’ and other firms’ EPS. Key data include S&P Case-Shiller (March), jobless claims and durable goods (May 23/April), and Canada payroll employment and GDP.

baystreet.ca2 min
AUG 25
$PLTRHighAI 8/10

Palantir's Maven Is Now an Official Pentagon Program of Record. Here's What Guaranteed Budget Dollars Are Worth.

Palantir Technologies (PLTR) announced that its Maven Smart System, an AI-powered military platform, has been designated an official Pentagon program of record. This designation could secure $2.3 billion in funding over five years. Maven analyzes battlefield data and supports AI-enabled targeting, making it a key tool for the U.S. military. Palantir's government contracts, including Maven, contributed significantly to its revenue, with $809 million from U.S. government contracts in Q2, up 90% ye

yahoo.com2 min
AUG 25
$HRLLow

Hormel names ex-Tyson executive as new CFO

Hormel Foods appointed Ash Bhumbla, a former Tyson Foods executive, as its new CFO, effective September. Bhumbla succeeds Paul Kuehneman, who will remain a senior leader. Hormel reported strong Q2 results and is set to release Q3 earnings on Thursday, according to the company.

thepoultrysite.com1 min